US Pharma MarketingJapan’s FY26 price revision expands G1 repricing and drives price reduction - Pharmaceutical Technology
Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices on a spending basis across 15,800 products. The analysis reviews the FY26 price revision by comparing the recent NHI-related price adjustments with observed price changes for the overall Japanese market in April 2026. Japan performs scheduled biennial price adjustments as a cost-reduction method. Credit: Vitalii Stock via Shutterstock.com. Japan’s latest National Health Insurance (NHI) drug price revision for FY26 has now come into effect, with an average 4.02% reduction in drug prices on a spending basis across roughly 15,800 products.…
Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices on a spending basis across 15,800 products.
Source: Pharmaceutical Technology